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CAPSTONE EXPERIENCE 
Abstract  
Objectives: To evaluate the role of preexisting Angiotensin II receptor type I 
antibodies (AT1RAb) and anti-HLA antibodies in predicting mortality and cardiac 
allograft vasculopathy (CAV) among heart transplant patients. 
Methods:  In this retrospective cohort study, we included 114 adults who received 
heart transplant from January 1st, 2007 to December 31, 2014 and were followed up 
at Nebraska Medicine. 48 hours pre-transplant sera sample were used to detect 
antibodies. A cutoff of 10UL/ml was used for AT1RAb positive and mean 
fluorescence intensity of 3,000 and 1,500 were used for anti HLA class I and class 
II, respectively. Patients were positive for composite antibodies if they were positive 
for anti-HLA, or AT1R antibodies. Survival analysis was conducted to compare the 
risk for mortality or CAV between antibody positive and negative groups.  
Result: Participants who had positive composite antibodies had higher probability 
of having CAV (p=0.05). Participants who were negative for AT1RAb trended toward 
a lower risk of mortality or developing CAV compared to AT1RAb positive 
counterparts. 
Conclusion: Positive status for any of anti-HLA or AT1RAb increased the risk of 
CAV. AT1RAb positivity is possibly linked with higher risk of death or developing 
CAV. Future study can focus on verifying these trends and the potential interaction 
effect between anti-HLA and AT1R antibodies.  
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INTRODUCTION 
Heart transplantation is the treatment of choice for end-stage heart disease. 
Since the first human heart transplant in 1967, the number of heart transplantation 
has increased rapidly worldwide. According to the 2014 International Society for 
Heart and Lung Transplantation (ISHLT) official report, there were 104,027 heart 
transplants through June 30th, 2013 globally (Lund et al., 2014). In the United 
States, there were about 2,500 cases conducted in the year 2012 (The International 
Society of Heart and Lung Transplantation, 2014). Mortality rates in heart 
transplantation have been reducing for every ten years, with the mortality rate in 
the first year after transplantation is about 15% in the cohort of patients 
transplanted in 2006 to 2012 (Lund et al., 2014). There are several factors that are 
associated with a higher risk of death up to 1 year after transplant. These factors 
include recipients’ pre-transplant severity of illness (measured by pre-operation 
hospitalization, mechanical ventilation, and temporary mechanical circulatory 
support), history of dialysis or blood transfusion, renal failure, and older age (Lund 
et al., 2014).  
However, heart transplantation is not considered a curative therapy for heart 
disease because of the long-term complications or comorbidities. These 
complications include blood marrow suppression, opportunistic viral infection, 
malignancy, graft loss, graft dysfunction and even mortality (Griffin, Callahan, & 
Menon, 2012). Comorbidities, which contribute to graft failure and graft loss, are 
also common in heart transplant patients. The prevalence of chronic disease in heart 
transplant patients higher than that in general population, and increase with post-
transplantation course. Specifically, prevalence of hypertension, hyperlipidemia, 
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cardiac allograft vasculopathy, and diabetes at 10 year post-transplantation are 97%, 
93%, 59% and 39% respectively (The International Society of Heart and Lung 
Transplantation, 2014). Nonetheless, estimation of comorbidities at certain 
predetermined time point, such as ten year, does not account for dead patients and 
therefore underestimate the real prevalence.  
Recipient selection 
In general, patients are considered for heart transplantation when they have 
severe heart failure that does not response with medical or mechanical treatment. 
Peak exercise maximum oxygen consumption and percentage to predict maximum 
oxygen consumption are usually used to objective evaluate heart function. Common 
indications for heart transplantation are listed in Table 1 (Pham, Berry, & Hunt, 
2011): 
Table 1: Commonly Accepted Indications for Cardiac Transplantation 
• Systolic heart failure with severe functional limitations or refractory 
symptoms despite maximal medical and device therapy 
• LVEF usually <35%, but a low LVEF is not an adequate indication for 
transplantation 
• NYHA functional class III-IV 
• Maximal oxygen uptake (VO2max) of ≤12-14 cc/kg/min exercise testing 
• Cardiogenic shock not expected to recover 
• Acute myocardial infarction 
• Acute myocarditis 
• Ischemic heart disease with intractable angina not amenable to surgical or 
percutaneous revascularization and refractory to maximal medical therapy 
• Intractable ventricular arrhythmias, uncontrolled with standard 
antiarrhythmic therapy, device therapy, or ablative therapy 
• Severe symptomatic hypertrophic or restrictive cardiomyopathy 
• Congenital heart disease in which severe, fixed pulmonary hypertension is 
not a complication 
• Cardiac tumors with a low likelihood of metastasis 
LVEF: Left ventricular ejection fraction. NYHA: New York Heart Association 
 
 4 
 
Before being selected for transplantation, heart failure patients need to 
undergo a series of tests and examination to ensure that they will be an appropriate 
recipient. These measurements include clinical examination, family, social and 
medical history, standard serum and a 12-h urine collection laboratory tests.  
Table 2: Contraindications for cardiac transplantation (Liao & 
Shumway, 2014) 
Relative contraindication:  
• Advanced age (>70) 
• Active myocarditis 
• Graft failure due to acute rejection 
Temporary contraindications for cardiac transplantation 
• Active infection 
• Active peptic ulcer disease 
• Diverticulitis 
• Recent pulmonary/cerebral emboli 
• Symptomatic cholelithiasis 
Absolute contraindications for cardiac transplantation 
• Positive prospective cross-match 
• Irreversible pulmonary hypertension (pulmonary vascular resistance ≥ 5 
Wood units) 
• Malignancy 
• Severe peripheral or cerebral vascular disease 
• Irreversible renal dysfunction (Glomerular Filtration Rate ≤40 ml/min) 
• Irreversible hepatic dysfunction 
• Severe obstructive or restrictive lung disease 
• Coexisting systemic disease 
• Diabetes mellitus with end-organs disease 
• Morbid obesity (≥30% or predicted ideal weight) or BMI ≥ 35 
• Severe cachexia 
• Ongoing tobacco use or drug addiction 
• Ongoing alcohol abuse 
• Noncompliance with medications 
• Inability to fully understand the procedure and participate in follow-up care 
 
Potential receivers are also ruled out of cancer with negative results from 
stool guaiac, mammography, prostate-specific antigen screening, Pap-smear. Tests 
of occult infections including hepatitis B and C, HIV, HTLV1, and HTLV2, 
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cytomegalovirus, Toxoplasma, Epstein–Barr virus, syphilis, and tuberculosis are 
also carried out before selection for transplantation is made. Pre-transplant data 
also include blood type, HLA–DR typing, and panel reactive antibody (PRA) 
screening (Liao & Shumway, 2014). Certain conditions that limit patients from 
being a recipient are listed in Table 2. 
Donor selection 
The donors are usually younger than 50 year old and do not have history of 
chest trauma or heart disease. Donor exclusion criteria include: malignancy with 
potential of metastasis to the heart, systemic sepsis or endocarditis, significant 
coronary artery disease, anatomical heart disease or poor ventricular function. 
While waiting for transplantation, the donor heart need to avoid prolong 
hypotension or hypoxemia. However, inotrope should be used as least as possible to 
reduce the oxygen demand of the donor heart. 
There are several technique to preserve the donor heart, including 
hypothermia, cardioplegia, and preservation solutions. Cardioplegia is used to 
arrest the heart while preservation solution is used to keep the heart at 4 to 8 Celsius 
degree to reduce metabolism. However, all measures together, the donor heart is 
usually only kept for to 4-6 hour of cold ischemic time. Due to the shortage of donors 
and the increasing demand, the selection of donor heart is widening beyond some 
classic contraindications. These expended criteria include longer ischemic time, 
mild valvular abnormalities, mild coronary artery abnormalities or mild left 
ventricular dysfunction (Pham et al., 2011).  
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Matching recipients and donors 
In order to anatomically matched heart size, the donors’ and recipients’ 
weight should also stay in the range from 80% to 120% of each other. However, body 
weight is not a sensitive tool to estimate the heart size. Chan et al. reported no 
correlation between body weights and heart size in adults who weigh from 40 to 99 
kg (Chan et al., 1991). With the expansion of donor pool, older donors are becoming 
more common. In such cases, an older recipient with similar life expectancy is 
usually chosen for transplant (Esmore, 2005). Donor and recipient should have the 
same ABO blood group, or compatible blood group. Recipients are also tested for 
panel reactive antibody (PRA). Potential recipients in the transplant waiting list who 
have PRA positive more than 20% should be checked for their antibody status every 
two months. A PRA test positive more than 20% just before transplant requires 
actually donor-specific T cell cross-matches to see if donor specific antibodies are 
present in recipients. Positive cross-matches are also a contraindication to 
transplantation (Esmore, 2005).  
Cardiac allograft vasculopathy 
Cardiac allograft vasculopathy (CAV) is the most important chronic 
comorbidity in heart transplant patients. CAV is the leading single cause of re-
transplantation in the US, accounting for 59% of total cases (Lund et al., 2014), and 
is associated with higher mortality rate at one year or five years after transplantation 
(Taylor et al., 2009). The mechanism of CAV is multifactorial, with the involvement 
of immune and non-immune factors (Griffin et al., 2012). These mechanisms 
include conventional risk factors for atherosclerosis, pre- and perioperative injury 
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to the graft vessels, innate immunity, cell-mediated rejection and antibody-
mediated rejection (Pober, Jane-wit, Qin, & Tellides, 2014).  
Table 3: ISHLT nomenclature for cardiac allograft vasculopathy 
(Mehra et al., 2010) 
ISHLT CAV0 
• Not significant No detectable angiographic lesion 
ISHLT CAV1  (Mild) 
• Angiographic left main (LM) < 50%, or primary vessel† with maximum lesion 
of <70%, or any branch‡ stenosis <70% (include diffuse narrowing) without 
allograft dysfunction§ 
ISHLT CAV2 (Moderate) 
• Angiographic LM <50%; a single primary vessel ≥70% or isolated branch 
stenosis ≥70% in branches of 2 systems, without allograft dysfunction 
ISHLT CAV3 (Severe) 
• Angiographic LM ≥50% or two or more primary vessels ≥70% stenosis, or 
isolated branch stenosis ≥70%, or ISHLT CAV1 or CAV2 with allograft 
dysfunction or evidence of significant restrictive physiology$ 
†A “primary vessel” denotes the proximal and middle 33% of the left anterior 
descending artery, left circumflex, the ramus and the dominant or co-dominant 
right coronary artery with the posterior descending and posterolateral branches. 
‡A “secondary branch vessel” includes the distal 33% of primary vessels or any 
segment within a large septal perforator, diagonals or obtuse marginal branches 
or any portion of a non-dominant right coronary artery. 
§Allograft dysfunction is defined as left ventricular ejection fraction ≤45% usually 
in the present of regional wall motion abnormalities. 
$Restrictive cardiac allograft physiology is defined as symptomatic heart failure 
with echocardiographic E to A velocity ratio >2 (>1.5 in children), shortened 
isovolumetric relaxation time (<60 msec), shortened deceleration time (<150 
msec), or restrictive hemodynamic value (right atrial pressure > 12 mmHg, 
pulmonary capillary wedge pressure >25 mmHg, cardiac index < 2l/min/m2) 
 
The underlying pathology of CAV is a progressive, proliferative, diffuse, 
chronic inflammatory condition of allograft coronary arteries. The morphology of 
CAV is concentric intimal thickening with outward remodeling, which makes it 
difficult to diagnose by conventional angiography. Current antilymphocyte and 
immunosuppressant have not yet yielded promising results to prevent or treat CAV. 
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Therefore, identifying patients at risk and applying rigorous prevention is the 
current strategy to deal with CAV. 
The risk of developing CAV is higher in patients of female gender, or with 
elevated pre-transplant panel-reactive antibodies (PRAs), de novo donor-specific 
antibodies (DSA) after transplantation, positive donor-specific crossmatch, prior 
sensitization to OKT3, cytomegalovirus (CMV) seropositivity, prior implantation of 
a ventricular assist device, and re-transplantation (J. Kobashigawa et al., 2011). 
Immunosuppressive agents such as cyclosporine or corticosteroid are also thought 
to contribute to endothelial cell injury, and ultimately to hyperplastic characteristic 
of CAV. 
Mortality 
The median survival time of heart transplant is 10 years. The mortality rate 
is highest in the first year, primarily due to graft failure and infection. For patients 
who survive the first year, the median survival time is 13 years. The improvement of 
survival in the first year after transplantation contributes greatly to the general 
improvement of survival of heart transplantation in the past decades, while long 
term survival has not changed much.  
Factors associated with mortality post-transplantation vary by time. For the 
first year, mechanical circulatory bridging support, ischemic heart disease, renal 
failure and mechanical ventilation are among the most significant attributors to 
mortality. From one to ten years after transplantation, in addition to prior factors, 
history of previous stroke, female donor or recipient are also associated with higher 
mortality (David D. Yuh, Luca A. Vricella, Stephen C. Yang, John R. Doty, 2014). 
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Antibodies in heart transplantation 
Human leukocyte antigen (HLA) antibodies are an important predictive 
factor for allograft failure (J. A. Kobashigawa, 2007; Nikaein, Alivizatos, Monahan, 
& Stone, 1995). The association between anti-HLA antibodies and cardiac allograft 
rejection was first described in the 1970s (Vasilescu et al., 2004). Since then, 
numerous studies have shown that the development of DSA to the HLA increased 
the risk of developing CAV in heart transplant patients (Raess et al., 2013; Reed et 
al., 1996; Suciu-Foca et al., 1991). The mechanism by which preexisting anti-HLA 
adversely affect transplant outcome has not been understood clearly. The presence 
of anti-HLA, although not directly specific against donor graft, is still associated 
with rejection post-transplant. Loupy et al. reported C1q-bound anti-HLA positivity 
associated with 11 times higher risk of graft lost in kidney transplantation compare 
to non C1q-bound anti-HLA (Loupy et al., 2013). Loupy also suggested that 
preformed C1q-bound anti-HLA had better predictive value for graft rejection than 
complement dependent cytotoxicity. However, these results were still controversial 
because half of patients who had been positive for C1q-bound antibodies became 
negative post-transplant, and posed a smaller risk of rejection post-transplantation 
(Baid-Agrawal, Lachmann, & Budde, 2014).  
Recently, the role of non-donor specific antigen antibodies in graft rejection 
has been the subject of interest. These non-donor-specific antibodies include, but 
not limited to, antibodies against angiotensin II type 1 receptor, vimentin, 
endothelial cell antigens, cardiolipin, and cardiac myosin (Barz & Rummler, 2013; 
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Forman, Lin, Pascual, Denton, & Tolkoff‐Rubin, 2004; Jurcevic et al., 2001; Kalache 
et al., 2011; Warraich et al., 2000). 
Angiotensin II type 1 receptor (AT1R) is a transmembranous G-couple 
protein receptor, that mediates the majority of the physiologic effects of Angiotensin 
II, especially on blood pressure (Dzau, 2001). There are several pathways through 
which a human develops antibodies against AT1R. AT1RAb can develop similarly to 
HLA antibodies through blood transfusion, pregnancy, or prior transplant 
(Reinsmoen, 2013). AT1RAb activate AT1R and promote remodeling of allograft 
vasculature. AT1RAb was found to be associated with adverse outcomes in both 
heart and kidney transplantation (Reinsmoen, 2013). In heart transplantation, 
AT1RAb are linked to cell-mediated rejection (CMR), antibody-mediated rejection 
(AMR), and an early CAV onset at one year after transplant (Yamani et al., 2006). 
In kidney transplantation, AT1RAb are associated with AMR independently or 
synergistically with HLA class II DSA in pediatric patients (Kelsch et al., 2011; 
Reinsmoen, 2013). Reinsmoen et al. found an impact of AT1RAb and DSA positivity 
on the development of AMR and CMR at two years after transplant. However, the 
authors did not find a significant impact of AT1RAb and DSA positivity on the 
incidence of mortality or CAV (Reinsmoen et al., 2014). To our knowledge, the 
association between preexisting AT1RAb or anti-HLA antibodies with clinical 
outcomes, such as mortality or CAV has not been well studied in heart transplant 
patients.  
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Study specific aim 
Investigate whether the presence of antibodies against HLA or AT1R 
increases the risk for cardiac allograft vasculopathy or mortality in heart transplant 
patients.  
Study hypothesis 
We hypothesized the presences of at least one type of anti-HLA antibodies or 
Angiotensin II type 1 receptor antibodies increase the risk for the development of 
cardiac allograft vasculopathy or death in heart transplant patients. We also 
hypothesized that AT1RAb, when being considered alone, is associated with a higher 
risk of mortality or CAV. 
METHODS 
Study Design and participants 
This was a retrospective cohort study to investigate the association between 
antibody positivity and time to death or time to development of CAV. Eligible 
participants included patients aged 18 or above, who had heart transplantation from 
January 1st, 2007 to December 31, 2014 and received post-transplantation care at 
Nebraska Medicine. A total sample of 114 participants with at least one pre-
transplantation antibody test record was used for analysis. The study protocol was 
approved by University of Nebraska Medical Center Institutional Review Board. 
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Outcomes   
Our primary outcome was time to all-cause mortality and the secondary 
outcome was time to the first CAV diagnosis since transplantation. Time to death 
censored status calculated by time from transplantation to either the last visit or the 
last day of study (31st December 2014), whichever came first. Two researchers with 
formal cardiology training independently reviewed all available participants’ 
coronary angiographs. In case there were discrepancies of diagnoses between two 
researchers, the coronary angiography results from medical record were used as a 
third judgment. CAV was identified by coronary angiograph and allograft function 
and physiology following the International Society for Heart and Lung Transplant 
(ISHLT) 2010 guidelines. In our study, patients were considered to have CAV if they 
felt into one of the categories from ISHLT CAV1 to ISHLT CAV3 and not to have CAV 
if they were ISHLT CAV0. Time to CAV censored status was calculated by time from 
transplantation to either the last normal angiography or the last day of study (31st 
December 2014), whichever came earlier.                                     
Exposures  
The primary exposure was pre-transplant composite antibodies to donor, 
including preexisting anti-HLA antibodies class I and class II, and anti-AT1R 
antibodies (AT1RAb). Participants were considered positive for composite 
antibodies if they had antibodies against at least one type of HLA or AT1R. We also 
conducted exploratory analyses for AT1RAb alone as the secondary exposure. We 
detected anti-HLA antibodies using flow cytometric technology with LABScreen™ 
products. We incubated 48h-pretransplant sera with purified antigens-coated 
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microbeads and pre-optimized reagents. Any antibodies present in the patients’ sera 
bound to the antigens on the beads and then were bound by anti-human IgG labeled 
with R-Phycoerythrin (PE). We detected AT1RAb using ELISA assay. AT1RAb in 
patient’s serum was bounded by anti-human IgG labeled with peroxidase enzyme. 
Based on our laboratory protocol, AT1RAb was considered to be positive when 
plasma concentration greater than 10 U/ml. Mean fluorescence intensity >3,000 
and >2,500 were used as a cut off for HLA class I positive and HLA class II positive, 
respectively. 
Other measurements 
Sociodemographic information was obtained through electronic medical 
records. We categorized age as younger than 55, or 55 and above following the 
median age of 55 in our sample. We classified race as two groups: white and other 
races. Smoking status was divided into have ever been a smoker or have never been 
a smoker. In our sample, only 3 patients were smoking at the time of transplant. 
Heart disease diagnosis was either coded to ischemic or non-ischemic heart disease. 
Statistical analyses 
Participants’ baseline characteristics were described by univariate analyses. 
We used Chi-square test or Fisher’s exact test where appropriate to compare 
baseline categorical variables. We used two independent samples T-test and 
Wilcoxon-signed rank test to compare continuous variables. We conducted Kaplan-
Meier plot and a log-rank test to compare the time to event (death, CAV) by antibody 
strata. In addition to the analyses for primary exposure, exploratory analyses on a 
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sample of 67 patients who were tested for AT1RAb were also conducted. We used a 
2-sided alpha of 0.05 as the cut-off value for statistical significance. All the analyses 
were performed in SAS 9.3 statistical software. 
RESULTS  
In our sample of 114 patients, 25 patients were positive for anti HLA (22%) 
and 89 were negative (78%). A subsample of 67 were tested for AT1RAb, among 
them 57 were positive (85%) and 10 were negative (15%). 
Baseline characteristics 
The median age at transplantation was 55 years, ranging from 20 to 69 years. 
The distribution of age at transplantation was not different by antibody status (Table 
5). Males and whites were predominant, accounting for 80-90% of the sample. 
Current or past smoker tended to be more common among participants who were 
negative for all antibodies compared to the positive counterparts (68% vs. 54%, 
p=0.14). Similarly, hypertension tended to be more common among patients who 
were negative for all antibodies compared to those who were positive (86% vs. 73%, 
p=0.09). These results were also observed similarly for AT1RAb alone. The 
percentage of ischemic heart disease was seen equally (40%) between the positive 
and negative AT1R antibody group. However, when DSA and anti HLA were taken 
into consideration, ischemic heart disease was more commonly seen in the 
negativity group (62%) compared to the positive group (40%; p=0.03). Diabetes 
tended to be more common in the AT1RAb positive group than in the negative group 
(51% vs. 20%, p=0.09), whereas its distribution was not different (50%) between the 
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composite antibody positive and negative groups. More than 40% of participants 
who were positive for at least one type of antibodies had utilized LVAD before 
transplantation compared to just about 25% among participants who were negative 
for these antibodies (p=0.05). 
Survival analyses 
Time to death 
The overall mean follow up time was 69 months, ranging from 1 to 94 months 
post-transplantation. Survival probability tended to be higher in antibody positive 
group around the first 3 years. The probability of survival at 36 months post-
transplantation was 89% in the composite antibody negative group and 95% in the 
positive group (Figure 1-A). However, at the end of the study, survival probability of 
antibodies positive and negative groups were not different (p=0.29). Among 
participants with a valid AT1RAb test, the mean follow up time was 54 months, 
ranging from 1 to 57 months post-transplantation. Three years post-transplantation, 
100% of participants who were negative for AT1RAb survived and compared with 
94% of participants who were positive for AT1RAb (Figure 1-B). The difference was 
more prominent at the end of follow up. However, it did not reach the level of 
significant. 
Time to cardiac allograft vasculopathy 
The overall mean follow up time for CAV was 64 months, ranging from 3 to 
84 months post-transplantation. The probability of CAV-free at 36 months post-
transplantation was 88% in the composite antibody negative group, while 77% of 
positive group stayed free of CAV. The trend of developing CAV was not different in 
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the first 24 months after transplantation between the negative (22%) and positive 
(23%) groups (Figure 1-C). However, after 35 months, CAV-free time declined more 
rapidly in patients who had positive antibodies compared to those who were 
negative (p=0.05). History of ischemic heart disease showed a trend of increase CAV 
hazard, while hypertension associated with lower hazard. Both these trends did not 
meet significant level. History of LVAD use did not affect the risk of having CAV 
between composite antibody positive and negative groups. At 36 months post-
transplantation, 100% of AT1RAb negative patients stayed CAV-free, compared to 
only 74% in the AT1RAb positive group were free of that condition (Figure 1-D). The 
decline trend was more obvious later in the follow up time in AT1RAb positive group, 
although this comparison did not reach the level of significant (p=0.23).  
DISCUSSION 
With the improvement of survival in the first year after transplantation, 
identifying risk factors that are associated with longer term complication such as 
CAV and long-term mortality is the new focus to further improve prognosis of heart 
transplantation. In the present study, we found an increased risk for developing CAV 
among participants who had pre-formed antibodies to at least HLA or AT1R. 
Preexisting anti AT1R antibodies were commonly present among heart 
transplant patients in our study. The prevalence of preexisting AT1RAb was reported 
from 17% to 47% among kidney transplant patients (Giral et al., 2013; Taniguchi et 
al., 2013). Urban et al. reported a lower prevalence of AT1RAb (38%) among heart 
transplant patients, however, the authors used higher cutoff (17U/ml) compared to 
our study (10U/ml) (Urban, Gazdic, Slavcev, & Netuka, 2015). Among baseline 
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characteristics, history of LVAD use and ischemic heart disease were significantly 
associated with positivity of composite antibodies. Similar association was also 
noted between AT1RAb and history of LVAD use in our study and in another study 
in Germen with similar percentage of AT1RAb positive in LVAD group (Sandy von 
Salisch et al., 2013). The association between history of LVAD use and anti-HLA 
antibodies was reported before (Kaczorowski, Datta, Kamoun, Dries, & Woo, 2013). 
The mechanism by which LVAD patients became sensitized to alloantigen was not 
clear. It is proposed that the exposure of blood products via transfusion in LVAD 
implantation procedure could induce allosensitization (McKenna Jr., Eastlund, 
Segall, Noreen, & Park, 2002). However, Drakos et al. and Itescu et al. in 
independent studies found avoiding blood transfusion or applying leukocyte-
filtered cellular blood product did not reduce the risk of allosensitization (Drakos et 
al., 2007; Itescu, Ankersmit, Kocher, & Schuster, 2000). In our study, when 
considering the hazard of developing CAV, patients with history of LVAD use did 
not have higher hazard than patients without LVAD use. This finding was consistent 
with previous studies which found no risk of LVAD use on clinical outcome such as 
mortality or CAV post-transplantation (Baran et al., 2005), even though it was 
associated with positive HLA antibodies and allograft rejection (John et al., 2003).  
Our study’s results suggested that positive preexisting composite antibody 
participants had higher hazard of developing CAV compared to negative 
counterparts. Pre-transplant anti-HLA antibodies was not associated with CAV in a 
study by Gandhi (Gandhi et al., 2010). However, the sample size in that stud was 
relatively small (19 patients). Eschborn in a study with 92 patients found a higher 
prevalence of CAV among preexisting HLA antibody patients compared to negative 
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counterparts, but the authors failed to establish a statistical difference (Eschborn et 
al., 2013). The mechanism by which HLA antibodies acquire their effect on 
vasculopathy is mainly via transplant rejection. Circulating antibodies attack donor 
antigen on the graft, activate complement system, cause C4d deposition on 
endothelial cells and start inflammation processes. In our study, the difference of 
CAV risk was not evident in the first 24 months after transplantation between then 
composite antibody positive and negative groups. This finding was consistent with 
the knowledge that CAV usually develops later in the course of transplantation, in 
the relation with both cell mediated and antibody mediated chronic rejection. 
The increase risk of developing CAV also noted when only AT1RAb positivity 
was taken into account in our study. AT1RAb was found to be associated with early 
onset of microvasculopathy in heart transplant before (Hiemann et al., 2012). The 
transplant procedure itself or the ischemic condition post-transplant promotes the 
expression of AT1R on endothelial cells and the development of AT1RAb 
(Reinsmoen, 2013). Since Angiotensin II also functions as moderator for cell 
growth, apoptosis, fibrosis and inflammation (Ruiz-Ortega et al., 2001), 
upregulating AT1RAb is thought to be associated with endothelial activation, 
leading to smooth muscular cell proliferation and microvascular disease 
(Reinsmoen, 2013). In our study, all patients without antibody against AT1R were 
free of CAV in the follow up time while the patients with AT1RAb accumulated CAV 
along with time. Although the follow up time and the number of participants in the 
AT1RAb negative group were relatively shorter and smaller than those in the 
positive group (Figure 1-D), we expect to see the trend to continue when  more 
patients are enrolled and followed for a longer time in the future. 
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In our study, participants who were positive for either donor specific antigen 
or AT1R did not showed higher mortality hazard compared to negative counterparts. 
Although post-transplant anti HLA antibodies were found to increase the risk of 
mortality in heart transplant, preexisting antibodies against HLA were not clearly 
associated with mortality in these patients (Ho et al., 2011). Tambur et al. found that 
majority of pre-existing anti HLA antibodies do not act directly against donor 
antigen found by lymphocyte cross match (Tambur et al., 2000). Thus, these 
antibodies would not trigger vigorous immune activity against the allograft, 
especially under the immunosuppressive therapy post-transplantation. When 
AT1RAb was considered alone, there was a minor trend of worse survival outcome 
in positive participants after 24 months. Due to no event in the AT1RAb negative 
group and short follow up period, mortality hazard ratio was not calculated for 
AT1RAb status. This finding calls for further investigation on the role of preexisting 
AT1RAb on mortality in heart transplant patients. 
Our study has some limitations. First, our sample was relatively small, which 
reduced our ability to detect small differences or conduct subgroup analyses. The 
selection of participants based on availability of test results could have introduced 
selection bias. On the other hand, our study was among the first study to look at the 
predictive value of AT1RAb on CAV and survival in heart transplantation. The 
assessment of CAV was done by two independent researchers, which would reduce 
observer bias. Future studies would assess the relationship between antibodies and 
CAV or mortality over a longer period of time, or evaluate the potential interaction 
between AT1RAb and donor specific antibodies on clinical outcomes in heart 
transplant patients. 
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Importance of the Capstone project 
This study allowed us to better understand the involvement of donor specific 
antibodies and non-donor specific antibodies, more specifically, anti-HLA 
antibodies and AT1RAb in the development of cardiac allograft vasculopathy as well 
as survival. This knowledge can help cardiologists identify the best donor-receiver 
match for transplant as well as transplanted patients who are at higher risk for these 
conditions. Further, these knowledge can be translated into a more appropriate 
prevention or treatment strategy for high risk heart transplant recipients. 
 For the public health, the study’s finding can contribute to better outcomes 
of heart transplantation, including lower re-transplant rates, mortality and 
dysfunction in heart transplantation. Further, these better outcomes will result in 
more patients receiving heart transplant, less medical cost and more effective and 
efficient heart transplantation programs.  
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Table 5: Pre-transplantation characteristics of participants by 
positivity to pre-transplant antibodies (n=114) 
Characteristics 
Composite  antibodies‡  Anti AT1R antibodies 
Positive 
(n=70) 
Negative 
(n=44)  
p-value  
 
Not tested 
(n=47) 
Positive 
(n=57) 
Negative 
(n=10) 
p-value 
n (%) n (%)  n (%) n (%) n (%)  
Age   0.95    0.99* 
<55 33 (47) 21 (48)  20 (43) 29 (51)  5 (50)  
≥55 37 (53) 13 (52)  27 (57) 28 (49)  5 (50)  
Gender   0.67    0.99* 
Male  55 (79) 36 (82)  37 (79) 46 (81) 8 (80)  
Females 15 (21) 8 (18)  10 (21) 11 (19) 2 (20)  
Race   0.99*    0.99* 
White  64 (91) 40 (91)  44 (94) 51 (89)  9 (90)  
Others 6 (9) 4 (9)  3 (6) 6 (11) 1 (10)  
Smoking status†   0.14    0.49* 
Never smoker 31 (46) 13 (32)  15 (36) 26 (46) 3 (30)  
Ever smoker 36 (54) 28 (68)  37 (64) 30 (54)  7 (70)  
Heart disease   0.05    0.99* 
Ischemic 18 (40) 26 (59)  27 (57) 23 (40) 4 (40)  
Non-ischemic 42 (60) 18 (41)  20 (43) 34 (60) 6 (60)  
Diabetes   0.99    0.09* 
Yes 35 (50) 22 (50)  26 (55) 29 (51)  2 (20)  
No  35 (50) 22 (50)  21 (45) 28 (49) 8 (80)  
Hypertension   0.09    0.43* 
Yes 51 (73) 38 (86)  39 (83) 41 (72)  9 (90)  
No  19 (27) 6 (14)  8 (17) 16 (28) 1 (10)  
Hyperlipidemia   0.43    0.73* 
Yes 46 (66) 32 (73)  35 (74) 37 (65)  6 (60)  
No  24 (34) 12 (27)  12 (26) 20 (35) 4 (40)  
LVAD   0.05    0.17* 
Yes 30 (43) 11 (25)  11 (23) 28 (49)  2 (20)  
No  40 (57) 33 (75)  36 (77) 29 (51) 8 (80)  
AT1R: Angiotensin II type 1 receptor, LVAD: Left ventricular assist device. 
All the p-values are from Chi-Square test comparing the positive to the negative groups, otherwise 
stated. 
*p-values from Fisher’s exact test comparing the positive to negative group. 
†Sum less than total due to missing values. 
‡Composite antibodies positive if positive for at least one of anti-HLA class I and II or AT1R 
antibodies. 
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Figure 1: Post-transplantation survival time by composite antibody status (DSA class I, II, anti HLA class 
I, II and AT1RAB) in (A) or by AT1RAb in (B) and cardiac allograft vasculopathy (CAV) free time by 
composite antibody status in (C) or by AT1RAb in (D). 
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SERVICE LEARNING REFLECTION 
Organization 
DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, UNMC 
The Division of Cardiology has 23 physicians. Its physicians are subspecialized in 
cardiac electrophysiology, interventional cardiology, diagnostic cardiovascular 
imaging, heart failure and heart transplantation (University of Nebraska Medical 
Center, 2014). 
ORGANIZATION FUNCTION 
The division of Cardiology functions as both a treatment center and an 
academic center. The Division provides patient care services to all adults with 
various type of cardiovascular disease, ranging from ischemic heart disease, valvular 
heart disease, arrhythmia, heart failure, and heart transplantation care. The 
cardiologists work closely with thoracic surgeons to provide the exceptional, 
comprehensive medical and surgical cardiovascular care. 
In addition to patient care services, the Division of Cardiology providing 
support for medical student, resident, and cardiology fellow training. The Division 
also offers clinical and research oriented conferences. The Division is also actively 
involved in research, ranging from bench research to clinical and community based 
research (University of Nebraska Medical Center, 2014). 
ORGANIZATION AIMS 
• Working with surgical partners to become a destination for patients to 
receive exceptional, comprehensive medical and surgical cardiovascular care. 
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• Be nationally recognized for our research programs. 
• Be a leader in innovative educational programs for students, house officers 
and clinicians across the region and provide 
• Attract and retain top clinicians, educators and scientists. 
Service performed 
The Service learning activities was conducted in the 2015 spring semester, 
from January 2015 to May 2015. The goal of the service that student provides to the 
site was to create a dataset that contains heart transplant patients which would be 
used for future research activities. 
 A part of the Service Learning activities, the student reviewed coronary 
angiographs of heart transplant patients. The results then transferred into electronic 
records with corresponding anatomical lesions. For each patient, the coronary 
angiograph results included the latest test, if those patients did not have any 
coronary artery lesion on the film, or the earliest angiograph that showed abnormal 
anatomy if they had coronary artery lesions.  
Student also reviewed echocardiograph and cardiac catheterization results 
from the medical record system (EPIC) for patients who have lesions on coronary 
angiography. The results were recoded into electronic form which contains left 
ventricular ejection fraction, right atrial pressure, pulmonary arterial pressure, 
diastolic function, and cardiac index. The results of coronary angiography, 
echocardiography and cardiac catheterization then graded for diagnosing of cardiac 
allograft vasculopathy following the International Society of Heart and Lung 
Transplantation guidelines.  
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In the second part of the Service learning, the student created an online 
database using REDCap web application. The REDCap database contained heart 
transplant patients currently in the research projects of the Cardiology Division. The 
variables were organized by variable domains, which included pre-transplantation 
variables, post-transplantation variables and donor-related variables. The database 
is able to be added more records in the future when the projects go on. Access and 
right of modification to the database can be granted by Dr. Brian Lowes. The 
REDCap database will be maintained and used for research activities of the Division 
in the future.  
Learning experience 
When I came to UNMC, Vietnam started heart transplant program with the 
first four patients. Sadly, after 6 months, all patients died because of acute rejection, 
a catastrophic complication that has been well prevented and treated in the US for 
the last ten years. The service learning and capstone project provides me a 
wonderful opportunity to pursuit my interest and apply my knowledge and skills. 
The first thing I learned from this project was current literature on heart 
transplantation, which provided me a more comprehensive view of transplantation 
process, from selecting the patients, selecting donor, screening and matching donor-
recipient, post-transplant care and especially the role of antibodies in heart 
transplantation. From literature review, I also identified potential risk factors for 
mortality or CAV in heart transplant recipients. This knowledge was applied to 
identify potential confounders or interactions in our analysis plan. Secondly, this 
was my first time to conduct a longitudinal study. I have learned the vital role of 
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time measurement for both exposures and outcomes, and how an obscure 
measurement could largely distort the relationship. More important, I learn how to 
apply epidemiology to test a scientific hypothesis, and ultimately to improve quality 
of patient care and common health at large.  
The second big gain was my experience of using REDCap. REDCap is a secure 
web application, developed by Vanderbilt University, for building and managing 
online surveys and databases. The application offers many options for designing 
questionnaire, checking data quality, export data dictionary or copy the format and 
structure of the project to use in a similar study. There is also a REDCap shared 
library of validated instruments and forms that can be easily downloaded and used 
by researchers partnered with REDCap. While working on service learning, I had an 
opportunity to explore and use most of the relevant options in REDCap.  
The biggest challenge to me was how to coordinate and collaborate between 
a busy research team. The challenge can be as simple as how to set up a meeting 
with the committee members or with members in the team to more complicated as 
how to exploit the expertise of each member of the project in the most valuable way. 
For these challenge the best way for me was to discuss with my advisor and other 
students to collect their experience, and plan everything in advance.  
Administrative Resources 
Offices supplies such as paper, pen, copying and printing are self-supported 
by students and committee members. Student used SAS 9.3 statistical software for 
all the analysis. SAS 9.3 is provided free of charge to all College of Public Health 
students through secure clustered computers in the computer lab. Rooms for 
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committee meetings are located in College of Public Health, which is provided by 
the college for Service Learning and Capstone Projects. No travel will be needed to 
accomplish the course. Other costs will be covered by the student. 
Service Learning/ Capstone Experience Goals and Objectives 
Goal 1: Completing service learning in spring semester 
Objective 1: Creating a REDCap database for data entry. 
Objective 2: Read coronary angiographs of heart transplant patients 
Objective 3: Enter data into the REDCap project 
Goal 2: Completing capstone experience in summer semester 
Objective 1: Analyze data for study questions 
Objective 2: Write and review the Capstone Experience report and 
manuscript 
Objective 3: Prepare and defend the capstone experience and submit paper 
TIMELINE FOR SERVICE LEARNING AND CAPSTONE EXPERIENCE 
The timeline for Service Learning and Capstone Experience is depicted 
bellow:  
Table 4:  Timeline for Service Learning and Capstone Project 
 Spring Semester Summer Semester 
Service Learning   
Objective 1 X  
Objective 2 X  
Objective 3 X  
Capstone Experience   
Objective 1  X 
Objective 2  X 
Objective 3  X 
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ETHICS ISSUES REGARDING RESEARCH 
PROTECTION OF PERSONAL IDENTIFICATION  
Since the data that we used include critical personal identification of the 
patients, there was a chance that such information might accidently be disclosed 
and/or obtained by a third party without the authorization of participants. To avoid 
any unauthorized access, all the data were stored in encrypted computer inside 
locked cabins or rooms. All personal identification was available only to the 
investigators. The access of personal identification to collaborators in the future can 
be safely granted by Dr. Lowes via REDCap project. All the statistics analysis was 
processed at secure computer lab at College of Public Health, UNMC. 
SAFETY OF SUBJECTS 
This was a retrospective study. All the information was available from the 
electronic health record system or in other hard copy forms. No procedure or 
medication was applied to patients for purpose of this study. Post-transplantation 
care was given to patients regardless of participation status. Other safety procedures 
were followed at the primary clinical trial and were approved by the UNMC IRB. 
Therefore, this study is considered to be minimal risk. 
CONFLICTS OF INTEREST 
The student and other researchers declare that they have no conflict of 
interest. The student, Hoang Tran, received a fellowship from the Vietnam 
Education Foundation to support his study at UNMC. The fellowship has no known 
benefits from this study. 
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APPLICATION OF PUBLIC HEALTH COMPETENCIES 
Competency 
Activity/Application 
Reflection of Competency Strength/ 
Professional Growth 
Committee 
Assessment 
CORE COMPETENCIES 
Competency 1B: Applied 
descriptive and inferential 
methodologies according to the 
type of study design 
Activity/Application: 
Applied univariate analysis with 
Chi-Square and Fisher’s Exact 
tests to describe the baseline 
characteristics. Applied Kaplan 
Meier curve and Log-Rank test 
to compare time to events. 
Applied Cox proportional 
regression to estimate hazard 
ratios for interest predictors 
This was my first time to apply survival 
analysis outside class. There were several 
factors that need to be considered when I 
conducted survival analyses which were not 
relevant to logistic regression analyses that I 
have done before. These factors such as time 
of exposure, or variability of exposures (DSA, 
AT1RAb) along the follow up time could 
affect the accuracy of the measurement and 
there for bias the results. These factors 
should always be taken account in the plan of 
data collection and efforts to identify these 
potential bias should be made in order to 
have accurate results. 
 Not 
Competent 
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
Competency 1C:  Interpret 
results of statistical analyses in 
public health studies. 
Activity/Application: 
Interpreted results from 
analysis, presented data in a 
variety of formats: table, plots, 
narrative.  
Interpreting the results in my project was 
challenging. Because of the unexpected 
missing data on CAV outcome, I have less 
power to detect small differences. For 
example, although the Kaplan Meier curves 
showed different patterns between the 
negative and positive exposure groups, the p-
value was still non-significant. Therefore, 
recognizing the trends or evaluating the 
absolute estimates, and confident intervals 
was important in interpreting the results 
rather than just focusing on p-value. 
 Not 
Competent 
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
Competency 3B:  Identify key 
sources of data for 
epidemiological purposes. 
Activity/Application: 
Identified potential source 
epidemiological data for 
Capstone Experience. 
I was able to identify several sources of 
epidemiological data such as Maine’s 
Behavior Risk Factor Survey (BRFSS), 
Veteran Affair Hospital Rheumatoid Arthritis 
Registry (VARA), and California Health 
Interview Survey. In my project, the data 
mainly came from NMC electronic medical 
records (EPIC). EPIC can be a very good 
source of research data with lots of 
information such as history, laboratory tests, 
comorbidities, procedures and treatments. 
However, some of the information was 
stored in an unextractable forms such as pdf 
or scanned pictures, which requires 
researchers to manually mine the data. 
 Not 
Competent 
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
Competency 7A: Identify and 
apply fundamental research skills 
in public health. 
From the Capstone experience paper, I was 
able to write a scientific manuscript which 
could be submitted for publication in a peer-
review journal. The challenge that I faced to 
 Not 
Competent 
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Activity/Application: Applied 
research skill to write a scientific 
manuscript. 
when I transformed the paper into the 
manuscript was the succinct format of the 
manuscript. Unlike the paper which was 
relatively flexible in format, the manuscript 
needed to be very concise, with around 3,000 
words to covey the study findings and 
discussion, in addition to a throughout and 
detailed method description.  
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
Competency 10A: Applied 
ethical principles to the collection, 
maintenance, use, and 
dissemination of public health 
information. 
Activity/Application: Secured 
patients’ confidentiality and safety 
throughout the study 
Although my study was a retrospective 
cohort study and no procedures, drugs or 
experiments were given to the patients, we 
dealt with lots of personal information which 
also need to be secured. I always adhered to 
patients’ information protection rule in my 
study. All the data were stored or transferred 
via HIPPA-compliant, secured server 
provided by UNMC information services. 
Data were not exposed to anyone who did 
not have the right to access determined by 
UNMC IRB.  
 Not 
Competent 
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
CONCENTRATION COMPETENCIES 
Competency 1A: 
Conceptualize epidemiologic 
research questions and 
hypotheses. 
Activity/Application: 
Created study objectives and 
hypotheses 
From literature review, I was able to identify 
the potential association between AT1RAb 
and CAV or mortality following heart 
transplant and propose the testable 
hypotheses through which AT1RAb affect 
heart transplant patients. I also identify the 
knowledge gap and proposed the study 
objective to fill in the gap.  
 Not 
Competent 
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
Competency 1C: Review and 
critique published 
epidemiologic studies. 
Activity/Application: 
Reviewed and critiqued 
published epidemiologic 
studies. Compared previous 
studies’ findings with the 
present study’s findings. 
There were a bundle of literature related to 
heart transplant and post-transplant 
complications or mortality. I was able to 
review the current literature to describe the 
donor-recipient selection process, which 
essential to understand the role of antibodies 
in rejection post-transplant. I also compared 
the findings in my study with previous 
studies, and discussed potential explanation 
for any differences among the findings.   
 Not 
Competent 
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
Competency 3A: Choose a 
study design appropriate for a 
particular epidemiologic 
question 
Activity/Application: Chose 
retrospective cohort study as 
the design for my Capstone 
project. 
Choosing the proper study design to test the 
study hypotheses is crucial. With the current 
data, I was be able to conduct a case-control 
study or a retrospective cohort study. The 
case-control study would be easier for me to 
conduct since I was familial with logistic 
regression. Since the study outcomes (CAV, 
death) would not occur at once, the case-
control study would not be able to reflect 
time to event and therefore would fail to test 
the hypotheses. On the other hand, a 
 Not 
Competent 
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
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retrospective cohort study would enable to 
measure time from transplant until the 
occurrence of outcomes, which will provide 
more information in the results, even with 
potential explanation of the underlying 
mechanism.  
Competency 4c: Identify 
potential sources and effects of 
bias in epidemiologic studies. 
Activity/Application: 
Identified potential bias in the 
present study and minimized 
the bias by analytical method. 
The present study employed time to event 
analyses. Besides the potential confounders 
that can affect the association (which 
partially adjust in multivariate analyses), 
time measurement of exposures or outcomes 
can also bias the results. For example, if the 
preexisting antibody status change, measure 
it at one point in time would potentially 
resulted in different result if it was measured 
in another time point. Therefore, the 
classification of patients to either exposed or 
non-exposed group could be changed. 
 Not 
Competent 
 Somewhat 
Competent 
 Competent  
 Highly 
Competent  
 Uncertain 
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